Every material Form 8-K Metagenomi Therapeutics, Inc. has filed with the SEC since June 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Metagenomi Therapeutics filed a Form 8-K furnishing its September 2026 corporate presentation as Exhibit 99.1 under Regulation FD. The presentation restates the company's cash position of $120.7 million at the end of Q2 2026, its runway through Q4 2027, and its timeline for MGX-001, its lead hemophilia A program.
Cash, cash equivalents and available-for-sale marketable securities were $120.7 million at end of Q2 2026, with runway anticipated through Q4 2027.
MGX-001 IND submission is planned for Q4 2026, with first patient dosing planned for 2027.
Preclinical data cited include 623 potential off-target sites tested, with no off-target edits identified in primary human hepatocytes at any dose.
Metagenomi reported second quarter 2026 results with a net loss of $27.5 million, or $0.73 per share, up from $19.9 million, or $0.54 per share, a year earlier. Collaboration revenue was negative $257 thousand, compared with $8.5 million in the second quarter of 2025, and the company ended the quarter with $120.7 million in cash and marketable securities, with runway anticipated through 4Q 2027. The company said it remains on track to submit an IND application for MGX-001 in hemophilia A in the fourth quarter of 2026.
Net loss was $27.5 million, or $0.73 per share, versus $19.9 million, or $0.54 per share, in Q2 2025.
Collaboration revenue was negative $257 thousand, compared with $8.5 million in Q2 2025.
R&D expenses were $22.5 million, flat year over year; G&A expenses fell to $6.0 million from $7.0 million.
Cash, cash equivalents and marketable securities were $120.7 million as of June 30, 2026, with runway anticipated through 4Q 2027.
Metagenomi director Brian C. Thomas resigned from the board effective June 9, 2026, with the company saying the resignation involved no disagreement on its operations, policies or practices. At the same day's annual meeting, shareholders re-elected... elected Juergen Eckhardt and Eric Bjerkholt as Class II directors and ratified PricewaterhouseCoopers LLP as auditor for 2026.
Brian C. Thomas resigned from the Board effective June 9, 2026; the filing states no disagreement with the company.
Juergen Eckhardt received 7,296,718 votes for and 1,436,882 withheld; Eric Bjerkholt received 8,251,289 for and 482,311 withheld.
Shareholders ratified PricewaterhouseCoopers LLP for fiscal 2026 with 18,483,295 for, 51,847 against and 581,065 abstentions.
Shares present or represented were 19,116,207 of 37,647,057 outstanding and entitled to vote, establishing a quorum.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Metagenomi Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →